CYP2C19基因多态性与山西汉族冠心病及其类型的相关性
作者:
作者单位:

(1.山西医科大学,山西省太原市 030001;2.山西医科大学第二医院心血管内科,山西省太原市 030001)

作者简介:

卫刚刚,硕士研究生,研究方向为冠心病基础与临床,E-mail 为295184288@qq.com。通信作者李瑾,硕士,教授,硕士研究生导师,研究方向为冠心病的基础与临床,E-mail为lijin2016@163.com。


Association of CYP2C19 gene polymorphism with coronary heart disease and its types in Shanxi Han population
Author:
Affiliation:

1.Shanxi Medical University, ;2.Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China)

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • | |
    摘要:

    目的 探讨CYP2C19基因多态性与山西汉族人群冠心病及其类型的关系。方法 回顾性收集2017年1月至2018年6月于山西医科大学第二医院心内科住院的来自山西各地无血缘关系的汉族患者693例,根据冠状动脉造影结果、临床表现、心电图、心肌损伤标志物结果,分为冠心病组478例(包括稳定型心绞痛50例,不稳定型心绞痛157例,急性心肌梗死271例),无冠状动脉病变组(对照组)215例,进行CYP2C19基因型检测,分析基因型与等位基因在两组间及冠心病不同类型间分布有无差异。结果 冠心病组CYP2C19*1/*2基因型分布频率高于对照组,差异有统计学意义(P=0.002);冠心病组CYP2C19*2 等位基因分布频率高于对照组,差异有统计学意义(P=0.011);对照组及冠心病三种不同类型间基因型、等位基因分布频率差异无统计学意义(P>0.05)。Logistic回归结果示:排除性别、年龄、糖尿病、吸烟史、高血压等因素的影响后,携带有CYP2C19*1/*2基因型者患冠心病的风险增加 (OR=1.838,95%CI 1.252~2.698)。结论 CYP2C19基因多态性是山西汉族冠心病发生的危险因素,但与冠心病的不同类型无相关性。

    Abstract:

    Aim To investigate the association of CYP2C19 gene polymorphism with coronary heart disease (CHD) and its types in Shanxi Han population. Methods 693 unrelated Han patients from Shanxi province were randomly collected from January 2017 to June 2018. According to the results of coronary angiography, clinical manifestations, electrocardiogram and myocardial injury markers, 478 cases were classified as CHD group (including 50 cases of stable angina pectoris, 157 cases of unstable angina pectoris, 271 cases of acute myocardial infarction), and 215 cases without coronary artery disease were classified as control group. Then, CYP2C19 genotypes were detected and the difference of genotype and allele distribution were observed and compared between the two groups. Results The frequency of CYP2C19*1/*2 genotype distribution in CHD group was higher than that in control group (P=0.002). The frequency of CYP2C19*2 allele distribution was higher in CHD group than that in control group (P=0.011). There was no significant difference in the frequency of genotype and allele distribution between the control group and three different types of CHD (P>0.05). Moreover, the Logistic regression analysis showed that the CYP2C19*1/*2 genotype was associated with the increased risk of CHD (OR=1.8,5%CI 1.252~2.698), when factors such as sex, age, diabetes, smoking history, hypertension were excluded. Conclusion CYP2C19 gene polymorphism is a risk factor for CHD in Shanxi Han population, but it is not associated with different types of CHD.

    参考文献
    [1] Bittner DO, Klinghammer L, Marwan M, et al.Influence of cardiovascular risk factors on the prevalence of coronary atherosclerosis in patients with angiographically normal coronary arteries.Acad Radiol, 7,4(5):580-586.
    [2] 李小雷, 杨惠月, 尚东升, 等.绝经前女性冠心病患者临床危险因素分析.中国动脉硬化杂志, 5,3(5):500-504.
    [3] Ye H, Zhou A, Hong Q, et al.Association of seven thrombotic pathway gene CpG-SNPs with coronary heart disease.Biomed Pharmacother, 5,2:98-102.
    [4] Polonikov A, Kharchenko A, Bykanova M, et al.Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.Gene, 7,7:451-459.
    [5] Caudle KE, Dunnenberger HM, Freimuth RR, et al.Standardizing terms for clinical pharmacogenetic test results:consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).Genet Med, 7,9(2):215-223.
    [6] 卫娜, 李俊男, 任俊峰, 等.肿瘤坏死因子受体2基因多态性与冠心病分型的相关性分析.中国动脉硬化杂志, 2,0(7):625-630.
    [7] 刘小艳, 刘涛.同型半胱氨酸及其代谢酶基因多态性与冠心病的关系.中国动脉硬化杂志, 8,6(1):55-59.
    [8] Knauer MJ, Diamandis EP, Hulot JS, et al.Clopidogrel and CYP2C19:pharmacogenetic testing ready for clinical prime time?.Clin Chem, 5,1(10):1235-1240.
    [9] Lin R, Zhang L, Zhang P, et al.Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.J Clin Pharm Ther, 5,0(3):308-314.
    [10] 王阳, 张志贤, 常福厚, 等.CYP2C19基因多态性与肝癌易感性关系的研究.中南药学, 2,0(7):481-485.
    [11] 金欣, 左向华, 薛剑, 等.细胞色素P450 2C19基因多态性与肺癌遗传易感性.标记免疫分析与临床, 4,1(5):564-567.
    [12] 张爱玲, 胡欣, 杨莉萍, 等.亚洲健康人群CYP2C19基因型发生率的合并分析.中国循证医学杂志, 4,4(4):427-434.
    [13] Hokimoto S, Tabata N, Akasaka T, et al.Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.J Cardiovasc Pharmacol, 5,5(2):148-152.
    [14] Ellinsworth DC, Sandow SL, Shukla N, et al.Endothelium-derived hyperpolarization and coronary vasodilation:diverse and integrated roles of epoxyeicosatrienoic acids, hydrogen peroxide, and gap junctions.Microcirculation, 6,3(1):15-32.
    [15] Oni-Orisan A, Edin ML, Lee JA, et al.Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans:a targeted metabolomics study.J Lipid Res, 6,7(1):109-119.
    [16] Collet JP, Hulot JS, Pena A, et al.Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction:a cohort study.Lancet, 9,3(9660):309-317.
    [17] Chen Y, Huang X, Tang Y, et al.Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.Int J Clin Exp Med, 5,8(6):9266-9274.
    [18] 张立国, 喻卓.CYP2C19基因多态性与云南汉族人群冠心病的相关性研究.中西医结合心脑血管病杂志, 6,4(14):1597-1600.
    引证文献
引用本文

卫刚刚,边云飞,李瑾. CYP2C19基因多态性与山西汉族冠心病及其类型的相关性[J].中国动脉硬化杂志,2019,27(8):708~712.

复制
分享
文章指标
  • 点击次数:651
  • 下载次数: 686
历史
  • 收稿日期:2019-01-21
  • 最后修改日期:2019-04-04
  • 在线发布日期: 2019-07-08